Blood in the urine
Pink, red or dark-brown urine — even once, even painless — always warrants investigation.
Genitourinary cancer covers the kidney, bladder and urinary tract (see also our dedicated prostate cancer page). Renal cell carcinoma and urothelial bladder cancer are the most common — and modern radiation now offers real options, including SBRT for kidney tumours in patients unsuitable for surgery.
Genitourinary cancers arise from uncontrolled cell growth in the organs of the urinary system. In the kidney, renal cell carcinoma (RCC) accounts for about nine in ten cancers — most commonly the clear cell subtype, with papillary and chromophobe variants less common. Transitional cell carcinomas arise not from the kidney itself but from the lining of the renal pelvis; Wilm's tumour affects children; renal sarcomas are rare.
In Singapore, renal cancers account for one to two percent of all cancers, while bladder cancer is among the ten most common cancers in men — and in its early stages, it can often be cured. Most bladder cancers are urothelial carcinomas arising from the cells lining the urinary tract, with rarer squamous cell, adenocarcinoma and small cell types.
The different types carry different outlooks and treatment plans — precise typing and staging come first.
Blood in the urine is the signature symptom across GU cancers — painless, sometimes intermittent, and never normal.
Pink, red or dark-brown urine — even once, even painless — always warrants investigation.
Persistent one-sided lower back pain not caused by injury.
A lump on the side or lower back.
Frequency, urgency or pain on urination that persists.
Tiredness, or anaemia found on blood tests.
Unexplained weight loss, fevers or night sweats in advanced disease.
Modern imaging characterises most kidney tumours without biopsy — while bladder cancer is diagnosed by looking directly.
Urinalysis confirms blood and checks for abnormal cells (cytology).
Multiphase CT characterises renal masses and maps the urinary tract.
A thin scope examines the bladder lining directly; suspicious areas are biopsied or resected.
CT of the chest and abdomen — with bone scan or PET where indicated — completes the stage.
Smoking is the leading preventable risk factor for both kidney and bladder cancer.
Doubles bladder cancer risk and significantly raises kidney cancer risk.
Industrial exposure to aromatic amines (dyes, rubber, leather industries) raises bladder cancer risk.
Both are established kidney cancer risk factors.
Long-term catheters, stones and recurrent infections raise squamous bladder cancer risk.
Von Hippel–Lindau disease and hereditary papillary RCC syndromes raise kidney cancer risk.
Risk rises with age; both cancers are more common in men.
Surgery leads for most operable GU cancers — but radiation's role has expanded decisively, especially for patients who can't have surgery.
Ablative stereotactic radiation offers hope for inoperable kidney cancer — precise, non-invasive, and delivered in a handful of sessions.
Bladder-preserving treatment — radiation with chemotherapy — as an alternative to bladder removal for suitable patients.
Daily image guidance manages bladder filling and organ motion across every pelvic course.
Checkpoint inhibitors are now standard in advanced kidney and bladder cancer — sequenced with radiation in one plan.
Every plan at AARO goes through detailed contouring, dose simulation, and independent physics review before a single beam is delivered. We do this so the radiation hits exactly the tissue that needs it — and avoids the healthy tissue around it.
Our medical physicists and radiation therapists collaborate on each plan — contouring tumour and organs-at-risk, simulating dose distribution, and independently checking every parameter before delivery.
Imaging before each fraction confirms the target's position to the millimetre — so tight margins stay safe, and healthy tissue stays out of the high-dose region.
Each treatment session takes 15–30 minutes. You'll lie on a precision treatment couch beneath the linear accelerator. Positioning lasers and daily imaging align you to within a millimetre of the planned position.
You won't feel the radiation as it's delivered. There's no anaesthesia, no recovery time, and no overnight stay. Most patients drive themselves home after the session and return to normal activities the same day.
GU radiation at AARO is led by our genitourinary sub-specialists — including internationally published kidney SBRT expertise.
Book a 45–60 minute specialist consultation. We'll review your imaging and pathology, explain the options that apply to your case, and answer your questions.